- Home
- CHRS vs TVGN Comparison
CHRS vs TVGN Comparison
Compare CHRS & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- TVGN
- Stock Information
- Founded
- CHRS 2010
- TVGN 2020
- Country
- CHRS United States
- TVGN United States
- Employees
- CHRS 235
- TVGN N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- TVGN Blank Checks
- Sector
- CHRS Health Care
- TVGN Finance
- Exchange
- CHRS Nasdaq
- TVGN Nasdaq
- Market Cap
- CHRS 134.4M
- TVGN 174.4M
- IPO Year
- CHRS 2014
- TVGN N/A
- Fundamental
- Price
- CHRS $1.22
- TVGN $1.48
- Analyst Decision
- CHRS Strong Buy
- TVGN
- Analyst Count
- CHRS 4
- TVGN 0
- Target Price
- CHRS $5.38
- TVGN N/A
- AVG Volume (30 Days)
- CHRS 2.4M
- TVGN 4.9M
- Earning Date
- CHRS 03-12-2025
- TVGN 02-20-2025
- Dividend Yield
- CHRS N/A
- TVGN N/A
- EPS Growth
- CHRS N/A
- TVGN N/A
- EPS
- CHRS N/A
- TVGN N/A
- Revenue
- CHRS $304,340,000.00
- TVGN N/A
- Revenue This Year
- CHRS $2.47
- TVGN N/A
- Revenue Next Year
- CHRS N/A
- TVGN N/A
- P/E Ratio
- CHRS N/A
- TVGN N/A
- Revenue Growth
- CHRS 44.19
- TVGN N/A
- 52 Week Low
- CHRS $0.66
- TVGN $0.26
- 52 Week High
- CHRS $2.87
- TVGN $21.09
- Technical
- Relative Strength Index (RSI)
- CHRS 44.03
- TVGN 55.93
- Support Level
- CHRS $1.03
- TVGN $1.30
- Resistance Level
- CHRS $1.23
- TVGN $1.56
- Average True Range (ATR)
- CHRS 0.13
- TVGN 0.17
- MACD
- CHRS -0.02
- TVGN 0.01
- Stochastic Oscillator
- CHRS 38.89
- TVGN 38.52
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.